NKGen Biotech, Inc. announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for SNK01 NK cell therapy for the treatment of Parkinson's disease. SNK01 is an autologous, genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression, potentially addressing a novel approach to tackling Parkinson's disease. The FDA IND clearance enables NKGen to initiate a Phase 1/2a clinical trial evaluating the safety, tolerability, and exploratory efficacy of SNK01 in patients with PD.

The trial is designed to enroll up to 30 patients (20 receiving SNK01 and 10 receiving placebo). NKGen expects to begin the trial, with the first patient dosed, in the second half of 2024.